Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
GameStop swaps USD 1.4 billion convertible notes for Class A shares

GameStop swaps USD 1.4 billion convertible notes for Class A shares

ReutersReuters2026/08/03 10:00
  • GameStop agreed to privately exchange about $1.4 billion of 0.00% Convertible Senior Notes due 2030 and 2032 for Class A shares.
  • The exchange retires debt without cash, cutting long-term debt by about $1.4 billion; $1.1 billion of 2030 Notes remain, $1.7 billion of 2032 Notes remain.
  • Closing is expected around Sept. 23, 2026, subject to customary conditions.
  • Shares issued will be based partly on the stock’s 35-day VWAP starting Aug. 3, 2026, subject to a per-share price floor.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GameStop Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260803780124) on August 03, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma

GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.

智通财经2026/09/15 08:06
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma